145 related articles for article (PubMed ID: 27123491)
1. Synergism of FAK and tyrosine kinase inhibition in Ph
Churchman ML; Evans K; Richmond J; Robbins A; Jones L; Shapiro IM; Pachter JA; Weaver DT; Houghton PJ; Smith MA; Lock RB; Mullighan CG
JCI Insight; 2016; 1(4):. PubMed ID: 27123491
[TBL] [Abstract][Full Text] [Related]
2. Ikaros: Exploiting and targeting the hematopoietic stem cell niche in B-progenitor acute lymphoblastic leukemia.
Churchman ML; Mullighan CG
Exp Hematol; 2017 Feb; 46():1-8. PubMed ID: 27865806
[TBL] [Abstract][Full Text] [Related]
3. The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia.
Marke R; van Leeuwen FN; Scheijen B
Haematologica; 2018 Apr; 103(4):565-574. PubMed ID: 29519871
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells.
Klein F; Feldhahn N; Herzog S; Sprangers M; Mooster JL; Jumaa H; Müschen M
Oncogene; 2006 Feb; 25(7):1118-24. PubMed ID: 16205638
[TBL] [Abstract][Full Text] [Related]
5. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia.
Yao QM; Liu KY; Gale RP; Jiang B; Liu YR; Jiang Q; Jiang H; Zhang XH; Zhang MJ; Chen SS; Huang XJ; Xu LP; Ruan GR
BMC Cancer; 2016 Apr; 16():269. PubMed ID: 27067989
[TBL] [Abstract][Full Text] [Related]
7. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.
Mullighan CG; Miller CB; Radtke I; Phillips LA; Dalton J; Ma J; White D; Hughes TP; Le Beau MM; Pui CH; Relling MV; Shurtleff SA; Downing JR
Nature; 2008 May; 453(7191):110-4. PubMed ID: 18408710
[TBL] [Abstract][Full Text] [Related]
8. IKAROS isoform 6 enhances BCR-ABL1-mediated proliferation of human CD34+ hematopoietic cells on stromal cells.
Suzuki K; Ono R; Ohishi K; Masuya M; Kataoka I; Liu B; Nakamori Y; Ino K; Monma F; Hamada H; Kitamura T; Katayama N; Nosaka T
Int J Oncol; 2012 Jan; 40(1):53-62. PubMed ID: 21901249
[TBL] [Abstract][Full Text] [Related]
9.
Paolino J; Tsai HK; Harris MH; Pikman Y
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255194
[No Abstract] [Full Text] [Related]
10. Targeting of heme oxygenase-1 attenuates the negative impact of Ikaros isoform 6 in adult BCR-ABL1-positive B-ALL.
Lin X; Zou X; Wang Z; Fang Q; Chen S; Huang J; Zhe N; Yu M; Zhang Y; Wang J
Oncotarget; 2016 Aug; 7(33):53679-53701. PubMed ID: 27447561
[TBL] [Abstract][Full Text] [Related]
11. Illegitimate RAG-mediated recombination events are involved in IKZF1 Δ3-6 deletion in BCR-ABL1 lymphoblastic leukaemia.
Dong Y; Liu F; Wu C; Li S; Zhao X; Zhang P; Jiao J; Yu X; Ji Y; Zhang M
Clin Exp Immunol; 2016 Sep; 185(3):320-31. PubMed ID: 27198500
[TBL] [Abstract][Full Text] [Related]
12. Dominant-negative IKAROS enhances IL-3-stimulated signaling in wild-type but not BCR-ABL1(+) mouse BA/F3 cells.
von Palffy S; Bulaeva E; Babovic S; Kannan N; Knapp DJ; Wei L; Eaves CJ; Beer PA
Exp Hematol; 2015 Jul; 43(7):514-23.e1-2. PubMed ID: 25951974
[TBL] [Abstract][Full Text] [Related]
13. High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement.
Ge Z; Gu Y; Zhao G; Li J; Chen B; Han Q; Guo X; Liu J; Li H; Yu MD; Olson J; Steffens S; Payne KJ; Song C; Dovat S
Oncotarget; 2016 Aug; 7(31):49722-49732. PubMed ID: 27391346
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of IKZF1 deletion in adult B cell acute lymphoblastic leukemia: a meta-analysis.
Zhang W; Kuang P; Li H; Wang F; Wang Y
Ann Hematol; 2017 Feb; 96(2):215-225. PubMed ID: 27815723
[TBL] [Abstract][Full Text] [Related]
15. IKAROS Gene Deleted B-Cell Acute Lymphoblastic Leukemia in Mexican Mestizos: Observations in Seven Patients and a Short Review of the Literature.
Ruiz-Delgado GJ; Cantero-Fortiz Y; León-Peña AA; León-González M; Nuñez-Cortés AK; Ruiz-Argüelles GJ
Rev Invest Clin; 2016; 68(4):210-4. PubMed ID: 27623040
[TBL] [Abstract][Full Text] [Related]
16. The biology of Philadelphia chromosome-like ALL.
Roberts KG
Best Pract Res Clin Haematol; 2017 Sep; 30(3):212-221. PubMed ID: 29050694
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
[TBL] [Abstract][Full Text] [Related]
18. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
Gleixner KV; Schneeweiss M; Eisenwort G; Berger D; Herrmann H; Blatt K; Greiner G; Byrgazov K; Hoermann G; Konopleva M; Waliul I; Cumaraswamy AA; Gunning PT; Maeda H; Moriggl R; Deininger M; Lion T; Andreeff M; Valent P
Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283
[TBL] [Abstract][Full Text] [Related]
19. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
[TBL] [Abstract][Full Text] [Related]
20. The Genomic Landscape of PAX5, IKZF1, and CDKN2A/B Alterations in B-Cell Precursor Acute Lymphoblastic Leukemia.
Ou Z; Sherer M; Casey J; Bakos HA; Vitullo K; Hu J; Friehling E; Gollin SM; Surti U; Yatsenko SA
Cytogenet Genome Res; 2016; 150(3-4):242-252. PubMed ID: 28214896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
